Teclistamab for Newly Diagnosed Mayo Stage IIIB Light-chain Amyloidosis Patients, a Phase II Study
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This is a phase II study in patients with newly diagnosed Mayo stage IIIB immunoglobulin light-chain (AL) Amyloidosis to evaluate the efficacy and safety of teclistamab
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Biopsy confirmed AL amyloidosis
• Mayo 2004 stage IIIB
• dFLC ≥ 50mg/L
Locations
Other Locations
China
Peking Union Medical College Hospital
RECRUITING
Beijing
Contact Information
Primary
Kaini Shen
shenkaini3@sina.com
86-13693339884
Time Frame
Start Date: 2025-06-28
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 35
Treatments
Experimental: Teclistamab
Teclistamab will be administered via a subcutaneous injection
Related Therapeutic Areas
Sponsors
Leads: Peking Union Medical College Hospital